A Barth Syndrome Patient-Derived D75H Point Mutation in TAFAZZIN Drives Progressive Cardiomyopathy in Mice

dc.contributor.authorSnider, Paige L.
dc.contributor.authorSierra Potchanant, Elizabeth A.
dc.contributor.authorSun, Zejin
dc.contributor.authorEdwards, Donna M.
dc.contributor.authorChan, Ka-Kui
dc.contributor.authorMatias, Catalina
dc.contributor.authorAwata, Junya
dc.contributor.authorSheth, Aditya
dc.contributor.authorPride, P. Melanie
dc.contributor.authorPayne, R. Mark
dc.contributor.authorRubart, Michael
dc.contributor.authorBrault, Jeffrey J.
dc.contributor.authorChin, Michael T.
dc.contributor.authorNalepa, Grzegorz
dc.contributor.authorConway, Simon J.
dc.contributor.departmentAnatomy, Cell Biology and Physiology, School of Medicine
dc.date.accessioned2024-10-09T09:08:35Z
dc.date.available2024-10-09T09:08:35Z
dc.date.issued2024-07-27
dc.description.abstractCardiomyopathy is the predominant defect in Barth syndrome (BTHS) and is caused by a mutation of the X-linked Tafazzin (TAZ) gene, which encodes an enzyme responsible for remodeling mitochondrial cardiolipin. Despite the known importance of mitochondrial dysfunction in BTHS, how specific TAZ mutations cause diverse BTHS heart phenotypes remains poorly understood. We generated a patient-tailored CRISPR/Cas9 knock-in mouse allele (TazPM) that phenocopies BTHS clinical traits. As TazPM males express a stable mutant protein, we assessed cardiac metabolic dysfunction and mitochondrial changes and identified temporally altered cardioprotective signaling effectors. Specifically, juvenile TazPM males exhibit mild left ventricular dilation in systole but have unaltered fatty acid/amino acid metabolism and normal adenosine triphosphate (ATP). This occurs in concert with a hyperactive p53 pathway, elevation of cardioprotective antioxidant pathways, and induced autophagy-mediated early senescence in juvenile TazPM hearts. However, adult TazPM males exhibit chronic heart failure with reduced growth and ejection fraction, cardiac fibrosis, reduced ATP, and suppressed fatty acid/amino acid metabolism. This biphasic changeover from a mild-to-severe heart phenotype coincides with p53 suppression, downregulation of cardioprotective antioxidant pathways, and the onset of terminal senescence in adult TazPM hearts. Herein, we report a BTHS genotype/phenotype correlation and reveal that absent Taz acyltransferase function is sufficient to drive progressive cardiomyopathy.
dc.eprint.versionFinal published version
dc.identifier.citationSnider PL, Sierra Potchanant EA, Sun Z, et al. A Barth Syndrome Patient-Derived D75H Point Mutation in TAFAZZIN Drives Progressive Cardiomyopathy in Mice. Int J Mol Sci. 2024;25(15):8201. Published 2024 Jul 27. doi:10.3390/ijms25158201
dc.identifier.urihttps://hdl.handle.net/1805/43829
dc.language.isoen_US
dc.publisherMDPI
dc.relation.isversionof10.3390/ijms25158201
dc.relation.journalInternational Journal of Molecular Sciences
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectBarth syndrome
dc.subjectPatient-tailored Tafazzin mutant allele
dc.subjectProgressive cardiomyopathy
dc.subjectMitochondria
dc.subjectp53 pathway
dc.titleA Barth Syndrome Patient-Derived D75H Point Mutation in TAFAZZIN Drives Progressive Cardiomyopathy in Mice
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Snider2024Barth-CCBY.pdf
Size:
14.73 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: